NCT05099003 2026-04-14
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
225 trialsNCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06504381 2026-03-11
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Phase 1/2 Recruiting
NCT04454528 2026-03-10
BreastVAX
Abramson Cancer Center at Penn Medicine
Phase 1/2 Active not recruiting
NCT06434350 2026-03-02
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05491317 2026-02-19
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Genmab
Phase 1/2 Terminated
NCT07217990 2026-02-17
NoCUT-BC
Ohio State University Comprehensive Cancer Center
Phase 1/2 Not yet recruiting
NCT03529448 2026-02-12
GEINOCANN
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT01517451 2026-02-11
Radiation and Androgen Ablation for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT04588545 2026-02-09
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT05039632 2026-02-06
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT04599062 2026-01-29
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
Phase 1/2 Active not recruiting
NCT07312422 2026-01-26
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Zhejiang Provincial People's Hospital
Phase 1/2 Recruiting
NCT00508443 2026-01-15
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04728230 2025-12-18
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02481635 2025-12-08
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 1/2 Active not recruiting
NCT03687957 2025-11-25
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04373785 2025-10-21
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
Phase 1/2 Not yet recruiting
NCT02444741 2025-10-09
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT07196345 2025-09-29
TAS-102 Plus Radiotherapy in Elderly ESCC
Qianfoshan Hospital
Phase 1/2 Not yet recruiting
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03298893 2025-09-19
NiCOL
Institut Curie
Phase 1/2 Completed
NCT07177950 2025-09-17
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT05893654 2025-09-15
MELCOM
Hospital das Clínicas de Ribeirão Preto
Phase 1/2 Enrolling by invitation
NCT03148327 2025-07-15
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT04019262 2025-06-18
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03317327 2025-06-03
REPORT
Oslo University Hospital
Phase 1/2 Completed
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT04789486 2025-05-23
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT00429143 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Thomas Jefferson University
Phase 1/2 Completed
NCT03523351 2025-04-20
Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03958383 2025-04-18
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
Phase 1/2 Active not recruiting
NCT05784012 2025-03-13
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Recruiting
NCT04881032 2025-02-13
NANO-GBM
Centre Jean Perrin
Phase 1/2 Active not recruiting
NCT03043599 2024-12-20
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04278287 2024-12-13
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT02891161 2024-11-27
DUART
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT02927964 2024-10-16
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Stanford University
Phase 1/2 Completed
NCT03453164 2024-09-19
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Fukushima Medical University
Phase 1/2 Completed